Real-World Evidence: Geriatric Cannabinoid Pharmacotherapy & Adverse Effect Incidence in Patients Aged 65+
Real-World Evidence: Geriatric Cannabinoid Pharmacotherapy & Adverse Effect Incidence in Patients Aged 65+
Clinical registry findings on cannabinoid tolerability, polypharmacy interactions, and falls/cognitive impairment incidence in geriatric cohorts managed under physician supervision. Derived from longitudinal physician evaluations across 81,008 unique clinical cohorts and 130,447 structured follow-up encounters at CED Clinic, informed by Dr. Benjamin Caplan’s career oversight of 350,000+ patient evaluations.
Methodology & Observational Grounding
Unlike traditional pharmaceutical clinical trials that restrict inclusion criteria to single-diagnosis participants devoid of concurrent medications, the CED Clinic Real-World Evidence Registry captures the complex clinical reality of outpatient cannabinoid medicine. Patients in this cohort were systematically evaluated under board-certified physician supervision, with structured longitudinal tracking of symptom burden, medication de-escalation, adverse event incidence, and chemovar responsiveness.
Ethical Oversight & Data Governance: Observational registry analyses synthesize de-identified clinical records adhering strictly to HIPAA Safe Harbor de-identification standards (45 CFR § 164.514(b)) and satisfy criteria for secondary research exemption under HHS Common Rule 45 CFR § 46.104(d)(4). No patient health identifiers are stored or disclosed.
What does real-world evidence show regarding cannabinoids for Geriatric Care & Senior Wellness?
In patients aged 65 and older, real-world adverse events are overwhelmingly concentrated in unmonitored rapid-onset inhaled products. Conversely, slow-titration sublingual and oral formulations demonstrate excellent safety profiles with significant reductions in polypharmacy burden.
What is the clinical scale and data provenance of this Geriatric Care & Senior Wellness analysis?
This analysis synthesizes real-world clinical observations from Dr. Benjamin Caplan, MD, who has overseen more than 350,000 patient evaluations across his career (including supervising 250,000+ patients as former Chief Medical Officer of Canna Care Docs). The specific dataset reflects 81,008 outpatient cohorts and 130,447 structured clinical visits tracked in the CED Clinic Clinical Registry.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
“In patients aged 65 and older, real-world adverse events are overwhelmingly concentrated in unmonitored rapid-onset inhaled products. Conversely, slow-titration sublingual and oral formulations demonstrate excellent safety profiles with significant reductions in polypharmacy burden.”